Literature DB >> 7957342

Granulosa cell tumor of the ovary. A clinicopathological evaluation of 60 cases.

A Ayhan1, Z S Tuncer, R Tuncer, R Mercan, K Yüce, A Ayhan1.   

Abstract

The patients with granulosa cell tumor of the ovary constituted 7.6% (60/780) of all ovarian malignancies treated at our Institution. The mean age of patients at diagnosis was 53.1. The most frequent symptom was abnormal vaginal bleeding. Of the 60 patients, 36 had stage I, 2 had stage II, 16 had stage III and 6 had stage IV disease. Endometrial hyperplasia and adenocarcinoma were detected in 18 and 3 patients, respectively. Lymph node metastasis was detected in only one of 18 patients subjected to lymphadenectomy. Recurrent disease was observed in 3 of 36 patients with stage I disease. The overall 5-year survival was found to be 85.0% (51/60). This figure varied from 100.0% to 63.6% according to the stage. In patients with stage I disease, surgery with and without adjuvant therapy achieved the same 5-year survival rate. In advanced stage, 5-year survival rate dropped from 90.0% with no gross residual disease to 25.0% with residual disease more than 2 cm. In patients with stage I disease, surgery only seems to be the treatment of choice. In advanced stage, since residual disease after surgery effects survival significantly, an aggressive surgical approach is advocated.

Entities:  

Mesh:

Year:  1994        PMID: 7957342

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  2 in total

1.  Prognostic predictors and spread patterns in adult ovarian granulosa cell tumors: a multicenter long-term follow-up study of 108 patients.

Authors:  Ibrahim Egemen Ertas; Kemal Gungorduk; Salih Taskin; Levent Akman; Aykut Ozdemir; Rifat Goklu; Mustafa Cosan Terek; Aydin Ozsaran; Yilmaz Dikmen; Yusuf Yildirim; Firat Ortac
Journal:  Int J Clin Oncol       Date:  2013-10-29       Impact factor: 3.402

2.  A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.

Authors:  Elizabeth R Burton; Mark Brady; Howard D Homesley; Peter G Rose; Toshiaki Nakamura; Joshua P Kesterson; Jacob Rotmensch; J Tate Thigpen; Linda Van Le
Journal:  Gynecol Oncol       Date:  2015-11-23       Impact factor: 5.482

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.